

Muscular Dystrophy Duchenne Muscular Dystrophy (DMD)

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

Trial Status
Terminated

Trial Runs In
2 Countries

Trial Identifier
NCT02515669 WN40226
CN001-006

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to determine the safety and tolerability of RO7239361 in boys with Duchenne Muscular Dystrophy with any genetic mutation.

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT02515669 WN40226 CN001-006
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
≥5 Years & ≤ 10 Years

Healthy Volunteers
No
